Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S ADR (NY: NVO )

111.94 -0.01 (-0.01%)
Official Closing Price Updated: 7:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S ADR

< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
63 64 Next >
Bernie Sanders To Take On Ozempic, Wegovy, Weight Loss Drugs: 'Could Be Helpful, But They're Not Going To Be Helpful If People Can't Afford Them'
A hearing from the Senate led by Bernie Sanders will look at diabetes and the rise of weight loss drugs. 
Via Benzinga
Here's How Much You Would Have Made Owning Novo Nordisk Stock In The Last 10 Years
Via Benzinga
Why Viking Therapeutics Was Crushing It This Week
Nowadays, it's good to be a developer of next-generation weight loss drugs. 
Via The Motley Fool
Could Eli Lilly Beat Novo Nordisk in the Billion-Dollar Weight Loss Market?
These drugs address a rapidly growing market. 
Via The Motley Fool
Zoetis Stock A Good Companion For Your Portfolio? Shares Rising
Reflecting strong fundamentals, Zoetis stock boasts a best-possible A SMR Rating (sales+profit margins+return on equity) on an A-to-E scale. 
Via Investor's Business Daily
JNJ CEO Signals No Rush Into Weight-Loss Drug Realm, Emphasizes Different Priorities
Johnson & Johnson (NYSE: JNJ) has no immediate plans to venture into weight-loss drugs due to the existing competition saturation, as Chief Executive Officer  
Via Benzinga
Everyone Is Talking About This Stock. Is It a Good Long-Term Option?
This company famously helps manage a prevalent chronic illness. 
Via The Motley Fool
Will NOVO-NORDISK A/S-SPONS ADR breakout?
The technical analysis for NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) is highly positive, with a rating of 10 out of 10, suggesting a potential breakout. 
Via Chartmill
Obesity Drugs: Greater Weight Loss Linked to Prolonged Use of Novo Nordisk's Wegovy
A recent analysis of medical records and insurance claims data revealed that 40% of patients who received prescriptions for Novo Nordisk A/S's (NYSE: NVO) obesity treatment drug Wegovy in 2021 or 2022... 
Via Benzinga
Simply Good Foods: Winner in the Ozempic Weight-Loss Trend
Nutritional food and snacks producer The Simply Good Foods Co. (NASDAQ: SMPL) has seen its shares rocket higher on the weight-loss medication 
Via MarketBeat
Jim Cramer Highlights 'Transformational' Impact Of Weight Loss Drugs Like Ozempic: Focus Now On 'Potential Winners' From The Same Narrative
Via Benzinga
Roche, Pfizer Race To Find Next Ozempic As Pharma Giants Hustle To Join Obesity Treatment Market
Weight-loss drugs such as Ozempic and Mounjaro are the leading blockbusters for a new epidemic 
Via Benzinga
Roche Stock Rises On $3.1 Billion Deal For Obesity Drugmaker
Roche said it will spend up to $3.1 billion to acquire Carmot Therapeutics, a biotech firm developing obesity drugs. Roche stock gained on the news. 
Via Investor's Business Daily
Ozempic vs. Mounjaro:: Battle of the bulge
The year 2023 was a breakout year for glucagon-like peptide (GLP-1) weight-loss drugs, led by the popularity of Ozempic. Celebrity usage 
Via MarketBeat
Exposures Product Safety
Roche Joins Bandwagon To Challenge Novo Nordisk, Eli Lilly For Weight Loss Drugs
Roche Holding AG (OTC: RHHBY) has agreed to 
Via Benzinga
1 Stock-Split Stock to Buy Hand Over Fist in December, and 1 to Avoid Like the Plague
Among Nvidia, Amazon, DexCom, Shopify, Alphabet, Tesla, Palo Alto Networks, Monster Beverage, and Novo Nordisk, there's a historically cheap outperformer, as well as an industry leader that could... 
Via The Motley Fool
3 No-Brainer Growth Stocks to Buy in December
No analysis paralysis is required with these great stocks. 
Via The Motley Fool
Pfizer Tumbles After Abandoning Weight-Loss Pill
With shares already reflecting a post-COVID dearth of revenue streams, Pfizer's growth outlook recently took another hit as it halted development of its experimental weight-loss pill after a high rate... 
Via Talk Markets
An Important History Lesson for Gene-Editing Investors
Gene editing holds tremendous promise for patients and investors alike. But the road to success won't be easy. 
Via The Motley Fool
Is Eli Lilly a Better Stock to Buy and Hold Over the Next 10 Years Than Novo Nordisk?
Both of these stocks have been big winners this year. But one could be better positioned to extend that winning streak over the next decade. 
Via The Motley Fool
Advocacy for Wegovy: Denmark Signals Cost-Sharing Talks While Novo Spent Millions On Medical Community For Drug Promotion
Denmark's Health Minister, Sophie Lohde, has signaled the government's willingness to expand coverage for Novo Nordisk A/S's (NYSE: NVO) weight-loss drug Wegovy if the company shares some of the... 
Via Benzinga
Weight Loss Drugs And Associated Suicidal Thoughts - European Drug Regulator Seeks Clarifications From Drug Makers
European Medicines Agency (EMA) will request further clarifications from drugmakers of GLP-1 receptor agonists for diabetes and weight loss, including Novo Nordisk A/S's (NYSE: NVO) popular therapies... 
Via Benzinga
Weight Loss Drugs - Novo Nordisk A Primary Beneficiary In Obesity Space Currently Controlled By Two Players, Says Analyst
Cantor Fitzgerald has initiated coverage on Europe's most valuable company, Novo Nordisk A/S (NYSE: NVO). 
Via Benzinga
Pfizer Halts Development Of Twice-Daily Weight-Loss Drug; PFE Stock Slides
Pfizer said Friday it would not advance development of a twice-daily oral weight-loss drug because of its side effects. PFE stock fell. 
Via Investor's Business Daily
Dow Jones Hits 2023 High, Nasdaq Slips; Tesla Cybertruck, Salesforce In Focus: Weekly Review
Software earnings were strong, while the Fed is shifting toward rate cuts. 
Via Investor's Business Daily
Topics Economy Stocks
Exposures Interest Rates US Equities
Pfizer’s Stock Is Down 44% YTD As Woes Continue
Pfizer's shares plunged on Friday after the drugmaker halted the trial of its twice-daily obesity drug. 
Via Talk Markets
Will Novo Nordisk Be a Trillion-Dollar Stock by 2030?
Novo Nordisk stock has been a red-hot buy this year -- can it continue that trend through this decade? 
Via The Motley Fool
Novo Nordisk Sues Florida Compounding Pharmacies Over Impurities In Products Claiming To Contain Wegovy Ingredient
Novo Nordisk A/S (NYSE: NVO) has reportedly taken legal action against Florida compounding pharmacies, suing one and refiling a lawsuit against another, as it discovered impurities in their products... 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Eli Lilly's Weight-Management Drug Outperformed Ozempic. Is It Time to Buy?
Electronic health records say tirzepatide, the active ingredient in Mounjaro and Zepbound, is better at reducing weight than semaglutide, the active ingredient in Ozempic and Wegovy. 
Via The Motley Fool
Counterfeit Ozempic Raises Alarms - Lebanon Reports Hypoglycemia Cases
Lebanese health officials have reported eleven cases of severe hypoglycemia linked to suspected fake versions of Novo Nordisk A/S's (NYSE: NVO)  
Via Benzinga
< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
63 64 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.